AYVAKYT DIN 02551772
Status: Marketed
Holder: BLUEPRINT MEDICINES CORPORATION
Health Canada record
| Active ingredient(s) | AVAPRITINIB 50 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01EX18 AVAPRITINIB |
|---|
| Original market date | 02-Dec-2024 |
|---|
| Current status date | 02-Dec-2024 |
|---|
| Source | Health Canada DPD |
|---|
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AVAPRITINIB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02551764 | AYVAKYT | BLUEPRINT MEDICINES CORPORATION | Tablet | AVAPRITINIB 25 MG | Marketed |
| 02551780 | AYVAKYT | BLUEPRINT MEDICINES CORPORATION | Tablet | AVAPRITINIB 100 MG | Marketed |
| 02551799 | AYVAKYT | BLUEPRINT MEDICINES CORPORATION | Tablet | AVAPRITINIB 200 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 34039 | 2024-09-18 | New Drug Submission (NDS) | |
International API supply for AVAPRITINIB
1 active FDA Drug Master Files.
Request a quote for AYVAKYT
How to read a Canadian DIN record